By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Five Prime Therapeutics, Inc. 

1650 Owens Street
Suite 200
San Francisco  California  94158  U.S.A.
Phone: 415-365-5600 Fax: 415-365-5601


Company News
Five Prime (FPRX)'s Founder And CEO To Step Down In 2018 6/22/2017 6:22:20 AM
Protagonist (PTGX) Appoints Five Prime (FPRX) CEO, Lewis T. "Rusty" Williams, To Its Board Of Directors 6/8/2017 8:06:01 AM
Five Prime (FPRX) Presents Initial Clinical Trial Data From Phase I/II Trial Of Cabiralizumab In Pigmented Villonodular Synovitis (PVNS) At 2017 ASCO Annual Meeting 6/5/2017 12:53:49 PM
Five Prime (FPRX) Presents Updated Data From Phase I Trial Of Single-Agent FPA144 At 2017 ASCO Annual Meeting 6/5/2017 12:47:53 PM
Five Prime (FPRX) Welcomes Garry Nicholson To Board Of Directors 5/16/2017 10:55:17 AM
Five Prime (FPRX) Announces First Quarter 2017 Results And Provides Business Update 5/5/2017 11:33:22 AM
Five Prime (FPRX) To Announce First Quarter 2017 Financial Results And Host Conference Call On May 4 4/21/2017 11:04:46 AM
Five Prime (FPRX) Announces Completion Of Enrollment For The Phase II Part Of The Ongoing Trial Of Cabiralizumab For The Treatment Of Pigmented Villonodular Synovitis (PVNS) 4/11/2017 10:57:36 AM
Juno (JUNO), Five Prime (FPRX) are Quiet Winners at AACR 4/21/2016 6:16:52 AM
Bad News for Bay Area's Five Prime (FPRX) as GlaxoSmithKline (GSK) Walks Away from Cancer Drug Pact 3/11/2016 7:36:53 AM